ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Achaogen, Inc." (AKAO) Report Updated: Jul 17, 2017 | Print This Page

Get more stock ratings by Louis Navellier

"Achaogen, Inc." (AKAO)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology
Competitors: SBPH,CLVS,EXEL,MDXG

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: B down no change
Last Week: B same upgrade
Two Weeks Ago: C up downgrade
service keys

"Achaogen, Inc."© quotemedia

Company Profile

Achaogen, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the United States. The company is principally developing plazomicin, which is in Phase III combating antibiotic resistant enterobacteriaceae trials for the treatment of bacterial infections due to multi-drug resistant Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds that target infections caused by acinetobacter baumannii and pseudomonas aeruginosa. The company was incorporated in 2002 and is headquartered in South San Francisco, California.